Inogen Inc (NASDAQ:INGN) Director Raymond Huggenberger sold 13,000 shares of Inogen stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $116.19, for a total value of $1,510,470.00. Following the completion of the transaction, the director now owns 10,208 shares in the company, valued at approximately $1,186,067.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Raymond Huggenberger also recently made the following trade(s):

  • On Friday, December 15th, Raymond Huggenberger sold 14,000 shares of Inogen stock. The stock was sold at an average price of $119.92, for a total value of $1,678,880.00.

Inogen Inc (NASDAQ INGN) traded down $0.96 during trading on Thursday, reaching $114.99. The company’s stock had a trading volume of 99,522 shares, compared to its average volume of 174,217. The company has a market cap of $2,400.00, a PE ratio of 80.41, a price-to-earnings-growth ratio of 3.94 and a beta of 1.13. Inogen Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The business had revenue of $69.00 million for the quarter, compared to analysts’ expectations of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business’s revenue was up 26.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.25 EPS. research analysts forecast that Inogen Inc will post 1.19 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC lifted its holdings in shares of Inogen by 31.5% during the fourth quarter. Acadian Asset Management LLC now owns 6,980 shares of the medical technology company’s stock valued at $832,000 after purchasing an additional 1,674 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Inogen by 3.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 79,600 shares of the medical technology company’s stock valued at $9,479,000 after purchasing an additional 2,327 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Inogen by 7.2% during the fourth quarter. Louisiana State Employees Retirement System now owns 7,400 shares of the medical technology company’s stock valued at $881,000 after purchasing an additional 500 shares during the last quarter. Simplex Trading LLC purchased a new position in shares of Inogen during the fourth quarter valued at approximately $153,000. Finally, Atlantic Trust Group LLC purchased a new position in shares of Inogen during the third quarter valued at approximately $1,093,000.

Several analysts recently issued reports on the company. Zacks Investment Research cut Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Leerink Swann reissued an “outperform” rating and issued a $120.00 target price (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. BidaskClub cut Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Finally, Needham & Company LLC raised their target price on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Inogen presently has an average rating of “Hold” and a consensus price target of $102.71.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Inogen Inc (INGN) Director Sells 13,000 Shares of Stock” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/01/18/insider-selling-inogen-inc-ingn-director-sells-13000-shares-of-stock.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.